Amneal (AMRX) EVP Nikita Shah Reports Two Sales Totaling 120,832 Shares

Q: What insider transactions are reported for AMRX in this Form 4?

The filing reports that Executive Vice President Nikita Shah sold 114,492 shares on 08/22/2025 at a weighted-average price of $9.66 and 6,340 shares on 08/25/2025 at a weighted-average price of $9.50 .

Q: How many AMRX shares does the reporting person own after the reported transactions?

The Form 4 shows beneficial ownership of 146,403 shares following the reported sales.

Q: Who signed the Form 4 for the reporting person?

The form is signed by /s/ Denis Butkovic, Attorney-in-Fact with a date of 08/25/2025 .

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Insider sales by Amneal Pharmaceuticals officer. Nikita Shah, identified as Executive Vice President and reporting person, sold a total of 120,832 shares of Amneal Pharmaceuticals, Inc. (AMRX) in two transactions: 114,492 shares on 08/22/2025 at a weighted-average price of $9.66 and 6,340 shares on 08/25/2025 at a weighted-average price of $9.50. Following these disposals the filing shows beneficial ownership of 146,403 shares. The Form 4 was signed by an attorney-in-fact on 08/25/2025. The filing provides weighted-price ranges for the sales and offers to provide detailed per-transaction quantities on request.

Positive

None.

Negative

Officer sold 120,832 shares across two dates, reducing insider ownership to 146,403 shares
Form does not state whether the sales were made pursuant to a Rule 10b5-1 trading plan

Insights

TL;DR Insider sales totaling 120,832 shares at ~$9.60–$9.75 and ~$9.50 are disclosed; ownership reduced to 146,403 shares.

The filing documents voluntary disposition by an Executive Vice President, with two separate sale dates and weighted-average prices disclosed. This is a clear disclosure of liquidity events rather than option exercises or derivative activity; no purchases or derivative holdings are reported. The scale of the sale is explicitly stated but the filing does not provide context on whether sales were pre-planned under a 10b5-1 plan.

TL;DR Officer-level sales were executed over two days and properly reported on Form 4, reducing beneficial ownership.

The report meets Section 16 disclosure requirements by listing transaction dates, weighted-average prices, and post-transaction beneficial ownership. The signature by an attorney-in-fact is provided. The filing does not state whether trades were pursuant to a Rule 10b5-1 plan, so no compliance conclusion can be drawn from the content alone.

Insider Trade Summary

Net Seller: 120,832 shares ($1,166,223)

Net Sell 2 txns

Insider Shah Nikita

Role Executive Vice President

Sold 120,832 shs ($1.17M)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	6,340	$9.50	$60K
Sale	Class A Common Stock	114,492	$9.66	$1.11M

Holdings After Transaction: Class A Common Stock — 146,403 shares (Direct)

Footnotes (1)

The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.60 to $9.75 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.50 to $9.51 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

08/25/2025 - 04:27 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shah Nikita

(Last)

(First)

(Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BLVD.

(Street)

BRIDGEWATER

08807

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	08/22/2025		S		114,492	D	$9.66⁽¹⁾	152,743	D
Class A Common Stock	08/25/2025		S		6,340	D	$9.5⁽²⁾	146,403	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.60 to $9.75 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

2. The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.50 to $9.51 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions are reported for AMRX in this Form 4?

The filing reports that Executive Vice President Nikita Shah sold 114,492 shares on 08/22/2025 at a weighted-average price of $9.66 and 6,340 shares on 08/25/2025 at a weighted-average price of $9.50.

How many AMRX shares does the reporting person own after the reported transactions?

The Form 4 shows beneficial ownership of 146,403 shares following the reported sales.

Were any derivative securities reported on this Form 4 for AMRX?

No derivative securities are reported in Table II; the filing only discloses non-derivative common stock disposals.

Does the Form 4 indicate if the sales were part of a 10b5-1 plan?

The filing does not indicate that the transactions were made pursuant to a Rule 10b5-1 trading plan.

Who signed the Form 4 for the reporting person?

The form is signed by /s/ Denis Butkovic, Attorney-in-Fact with a date of 08/25/2025.